Brand Name | Status | Last Update |
---|---|---|
mylotarg | Biologic Licensing Application | 2021-09-03 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
myeloid leukemia acute | — | D015470 | C92.0 |
myelomonocytic leukemia acute | — | D015479 | C92.5 |
Expiration | Code | ||
---|---|---|---|
gemtuzumab ozogamicin, Mylotarg, Wyeth Pharmaceuticals LLC | |||
2024-09-01 | Orphan excl. |
Code | Description |
---|---|
J9203 | Injection, gemtuzumab ozogamicin, 0.1 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Electrocardiography | D004562 | EFO_0004327 | — | — | — | — | 1 | — | 1 |
Pharmacokinetics | D010599 | — | — | — | — | — | 1 | — | 1 |
Healthy volunteers/patients | — | — | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Leukemia | D007938 | — | C95 | 7 | 8 | 1 | — | 3 | 16 |
Myeloid leukemia acute | D015470 | — | C92.0 | 7 | 8 | 1 | — | 3 | 16 |
Myeloid leukemia | D007951 | — | C92 | 7 | 8 | 1 | — | 3 | 16 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 1 | 1 | — | — | — | 1 |
Residual neoplasm | D018365 | — | — | — | 1 | — | — | — | 1 |
Recurrence | D012008 | — | — | — | 1 | — | — | — | 1 |
Drug common name | Gemtuzumab ozogamicin |
INN | gemtuzumab ozogamicin |
Description | Immunoglobulin G 4 (human-mouse monocional hP67.674-chain anti-human antigen CD 33), disulfide with human-mouse monoclonal hP67.6x-chain, dimer |
Classification | Antibody |
Drug class | monoclonal antibodies; antibiotics (Micromonospora strains) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1201506 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB00056 |
UNII ID | 8GZG754X6M (ChemIDplus, GSRS) |